Neurological Disease

PF-04701475 is a potent AMPA receptor potentiator with an EC₅₀ of 123 nM. PF-04701475 can be used for the study of neurological disorders.

Valpromide (Standard) is the analytical standard of Valpromide (HY-B2117). This product is intended for research and analytical applications. Valpromide is an amide derivative of Valproic acid (HY-10585) and an orally active epoxide hydrolase inhibitor that can cross the blood-brain barrier. Valpromide has antiepileptic, anticonvulsant, and antipsychotic effects. Valpromide also exhibits antiviral activity and can inhibit the reactivation of the EBV lytic cycle.

TC-I 2014 (Standard) is the analytical standard of TC-I 2014 (HY-110199). This product is intended for research and analytical applications. TC-I 2014 (compound 5) is a potent and orally active Benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonist, with IC₅₀ values of 0.8 nM, 3.0 nM and 4.4 nM for canine, human and rat channels respectively. TC-I 2014 exhibits antiallodynic properties in pain models.

Loxapine (Standard) is the analytical standard of Loxapine. This product is intended for research and analytical applications. Loxapine is an orally active dopamine inhibitor, 5-HT receptor antagonist and also a dibenzoxazepine anti-psychotic agent.

Aminophylline (Standard) is the analytical standard of Aminophylline (HY-B0140). This product is intended for research and analytical applications. Aminophylline is a competitive phosphodiesterase 3/4 (PDE3/4) inhibitor. Aminophylline also acts as an adenosine receptor antagonist. Aminophylline elevates intracellular cAMP levels via competitive inhibition of PDE3 and PDE4, antagonizes adenosine A1 receptor (ADORA1), regulates intracellular calcium signaling and synaptic vesicle cycling, upregulates the PPAR signaling pathway, and downregulates glutamatergic synaptic pathways simultaneously. Aminophylline can be used in research related to major depressive disorder, epilepsy, asthma, and chronic obstructive pulmonary disease (COPD).

BIP-135 (Standard) is the analytical standard of BIP-135 (HY-111055). This product is intended for research and analytical applications. BIP-135 is a potent and selective ATP-competitive GSK-3 inhibitor, with IC₅₀s of 16 nM and 21 nM for GSK-3α and GSK-3β, respectively. BIP 135 exhibits neuroprotective effect.

AMG2850 (Standard) is the analytical standard of AMG2850 (HY-104059). This product is intended for research and analytical applications. AMG2850 is an orally active, blood-brain barrier-permeable selective TRPM8 competitive antagonist. AMG2850 abolishes the counterirritant effect of TRPM8 agonists, blocks TRPM8 activation induced by cold, (-)-Menthol (HY-75161) and Icilin (HY-11062), and exhibits selectivity over TRPA1, TRPV1, TRPV3 and TRPV4. AMG2850 is applicable for pain-related research.

NRMA-10, an amide prodrug, is a brain-penetrant nuclear receptor modulator. NRMA-10 increases brain expression of Adam10. NRMA-10 preferres distribution to the CNS compared to the periphery. NRMA-10 can be used for the study of central nervous system (CNS) disorders.

MMB-ICA is a metabolite of MMB-CHMICA.

(Z)-Doxepin is an isomer of Doxepin (HY-B0725A). Doxepin is an orally active, blood-brain barrier penetrant tricyclic antidepressant with multiple activities including hypnosis, sedation, analgesia and vasodilation. Doxepin enhances the expression of PSD-95 and synapsin 1 via the PI3K/AKT/mTOR signaling pathway, and is metabolized to Desmethyldoxepin in vivo. Doxepin can be used in research related to various diseases such as depression, anxiety, obesity and atopic dermatitis.

Iloperidone (Standard) is the analytical standard of Iloperidone. This product is intended for research and analytical applications. Iloperidone (HP 873) is a D2/5-HT2 receptor antagonist. Iloperidone is an atypical antipsychotic for the schizophrenia symptoms.

Fosaprepitant (dimeglumine) (Standard) is the analytical standard of Fosaprepitant (dimeglumine). This product is intended for research and analytical applications. Fosaprepitant dimeglumine (MK-0517) is a proagent of Aprepitant (HY-10052). Fosaprepitant dimeglumine is a neurokinin-1 receptor antagonist, which is development for the prevention of chemotherapy-induced nausea and vomiting (CINV).

Cloroperone is a 5-HT₂ receptor inhibitor with a K_i value of 4.5 nM. Cloroperone can be used in research on psychiatric disorders.

Vincanol ((-)-Isoeburnamine) is a blocker of voltage-gated Na+ channels. Vincanol blocks Na⁺ currents with an IC₅₀ value of 40 μM. Vincanol has neuroprotective effect.

Betahistine (dihydrochloride) (Standard) is the analytical standard of Betahistine (dihydrochloride). This product is intended for research and analytical applications. Betahistine dihydrochloride is an orally active histamine H1 receptor agonist and a H3 receptor antagonist. Betahistine dihydrochloride is used for the study of rheumatoid arthritis (RA).

Nicardipine (Standard) is the analytical standard of Nicardipine. This product is intended for research and analytical applications. Nicardipine (YC-93 free base) is a calcium channel blocker with an IC50 of 1 μM for blocking cardiac calcium channels. Nicardipine acts as an agent for chronic stable angina and for controlling blood pressure.

Lofexidine (Baq-168) hydrochloride Standard is the analytical standard of Lofexidine hydrochloride (HY-B1052). This product is intended for research and analytical applications. Lofexidine hydrochloride (Baq-168) is an orally active agonist of the imidazoline I1 receptor (imidazoline I1 receptor) (Ki: 1.9 nM) and α₂-adrenergic receptor (α2-adrenergic receptor). Lofexidine hydrochloride binds to the α₂A-adrenergic receptor, reduces sympathetic outflow, lowers blood pressure, and exhibits vasoconstrictive effects. Lofexidine hydrochloride regulates the expression of c-fos and alleviates opioid withdrawal symptoms. Lofexidine hydrochloride is applicable to research on opioid addiction and withdrawal.

Mephentermine is a sympathomimetic amine, frequently used as a vasopressor.

Alvelestat hydrochloride (AZD9668 hydrochloride) is an orally active, selective inhibitor of neutrophil elastase. Alvelestat hydrochloride reduces elastase activity, myeloperoxidase release, neutrophil recruitment and activation, and calcium phosphate precipitation; promotes smooth muscle cell colonization and collagen deposition; and inhibits the formation of neutrophil extracellular traps (NETs) as well as NET-derived neutrophil elastase activity. Alvelestat hydrochloride restores endothelial dysfunction, regulates antioxidant factors, improves the expression of endothelial tight junctions, reduces vascular leakage, and accelerates wound healing. Alvelestat hydrochloride prevents pulmonary hemorrhage, matrix protein degradation, airspace enlargement, and small airway wall remodeling; and alleviates cigarette-induced inflammatory responses. Alvelestat hydrochloride inhibits the growth of abdominal aortic aneurysms exacerbated by Porphyromonas gingivalis. Alvelestat hydrochloride can be used in research related to chronic obstructive pulmonary disease, abdominal aortic aneurysm, radiation-induced skin injury, and bronchiectasis.

(R)-(+)-HA-966 (Standard) is the analytical standard of (R)-(+)-HA-966 (HY-100822). This product is intended for research and analytical applications. (R)-(+)-HA-966 ((+)-HA-966) is a partial agonist/antagonist of glycine site of the N-methyl-D-aspartate (NMDA) receptor complex. (R)-(+)-HA-966 selectively blocks the activation of the mesolimbic dopamine system by amphetamine. (R)-(+)-HA-966 can cross the blood-brain barrier and has the potential for neuropathic and acute pain.